These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19896447)

  • 41. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
    Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
    Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
    Pierce KK; Whitehead SS; Kirkpatrick BD; Grier PL; Jarvis A; Kenney H; Carmolli MP; Reynolds C; Tibery CM; Lovchik J; Janiak A; Luke CJ; Durbin AP; Pletnev AG
    J Infect Dis; 2017 Jan; 215(1):52-55. PubMed ID: 28077583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.
    Lim CK; Takasaki T; Kotaki A; Kurane I
    Virology; 2008 Apr; 374(1):60-70. PubMed ID: 18221765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms.
    Chung KM; Nybakken GE; Thompson BS; Engle MJ; Marri A; Fremont DH; Diamond MS
    J Virol; 2006 Feb; 80(3):1340-51. PubMed ID: 16415011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
    Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
    Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.
    Minke JM; Siger L; Cupillard L; Powers B; Bakonyi T; Boyum S; Nowotny N; Bowen R
    Vaccine; 2011 Jun; 29(28):4608-12. PubMed ID: 21549780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. N-linked glycosylation of the West Nile virus envelope protein is not a requisite for avian virulence or vector competence.
    Maharaj PD; Langevin SA; Bolling BG; Andrade CC; Engle XA; Ramey WN; Bosco-Lauth A; Bowen RA; Sanders TA; Huang CY; Reisen WK; Brault AC
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007473. PubMed ID: 31306420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
    Martin JE; Pierson TC; Hubka S; Rucker S; Gordon IJ; Enama ME; Andrews CA; Xu Q; Davis BS; Nason M; Fay M; Koup RA; Roederer M; Bailer RT; Gomez PL; Mascola JR; Chang GJ; Nabel GJ; Graham BS
    J Infect Dis; 2007 Dec; 196(12):1732-40. PubMed ID: 18190252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring Anti-NS1 Antibodies in West Nile Virus-Infected and Vaccinated Horses.
    Rebollo B; Sarraseca J; Lecollinet S; Abouchoaib N; Alonso J; García-Bocanegra I; Sanz AJ; Venteo Á; Jiménez-Clavero MA
    Biomed Res Int; 2018; 2018():8309816. PubMed ID: 30356362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. West Nile 25A virus infection of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein.
    Chambers TJ; Droll DA; Walton AH; Schwartz J; Wold WSM; Nickells J
    J Gen Virol; 2008 Mar; 89(Pt 3):627-635. PubMed ID: 18272752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A live attenuated West Nile virus strain as a potential veterinary vaccine.
    Lustig S; Olshevsky U; Ben-Nathan D; Lachmi BE; Malkinson M; Kobiler D; Halevy M
    Viral Immunol; 2000; 13(4):401-10. PubMed ID: 11192286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.
    Hughes HR; Crill WD; Davis BS; Chang GJ
    Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.
    Widman DG; Ishikawa T; Fayzulin R; Bourne N; Mason PW
    Vaccine; 2008 May; 26(22):2762-71. PubMed ID: 18423946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.
    Gershoni-Yahalom O; Landes S; Kleiman-Shoval S; Ben-Nathan D; Kam M; Lachmi BE; Khinich Y; Simanov M; Samina I; Eitan A; Cohen IR; Rager-Zisman B; Porgador A
    Immunology; 2010 Aug; 130(4):527-35. PubMed ID: 20331473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus).
    Langevin SA; Arroyo J; Monath TP; Komar N
    Am J Trop Med Hyg; 2003 Jul; 69(1):78-80. PubMed ID: 12932102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.
    Dayan GH; Bevilacqua J; Coleman D; Buldo A; Risi G
    Vaccine; 2012 Oct; 30(47):6656-64. PubMed ID: 22959989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. West Nile virus vaccines - current situation and future directions.
    Ulbert S
    Hum Vaccin Immunother; 2019; 15(10):2337-2342. PubMed ID: 31116691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Twenty Years of Progress Toward West Nile Virus Vaccine Development.
    Kaiser JA; Barrett ADT
    Viruses; 2019 Sep; 11(9):. PubMed ID: 31491885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levels of Circulating NS1 Impact West Nile Virus Spread to the Brain.
    Wessel AW; Dowd KA; Biering SB; Zhang P; Edeling MA; Nelson CA; Funk KE; DeMaso CR; Klein RS; Smith JL; Cao TM; Kuhn RJ; Fremont DH; Harris E; Pierson TC; Diamond MS
    J Virol; 2021 Sep; 95(20):e0084421. PubMed ID: 34346770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.